Prevalence, Molecular Characteristics and Virulence Identification of Bovine Parainfluenza Virus Type 3 in China

Xiaowen Xu1,2,3, Wanyue Zhao1,2,3, Zhijie Xiang1,2,3

  • 1National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China.

Viruses
|March 28, 2024
PubMed

Insights

Bovine parainfluenza virus type 3 (BPIV-3) surveillance in China revealed a 4.64% cattle positive rate. Identified BPIV-3C strains offer insights for disease control and potential vaccine development.

Area of Science:

  • Veterinary Virology
  • Molecular Epidemiology
  • Bovine Respiratory Disease Complex

Background:

  • Bovine parainfluenza virus type 3 (BPIV-3) is a significant pathogen contributing to the bovine respiratory disease complex (BRDC).
  • Limited BPIV-3 surveillance data exists for China, hindering effective disease management strategies.

Purpose of the Study:

  • To investigate the prevalence and genetic characteristics of BPIV-3 in China.
  • To identify potential vaccine candidates for BPIV-3 control.

Main Methods:

  • Polymerase Chain Reaction (PCR) was employed to screen 302 cattle samples.
  • BPIV-3 strains were isolated, confirmed via electron microscopy, and titrated.
  • Next-generation sequencing (NGS) was utilized for genetic and phylogenetic analyses.
  • Virulence assays were performed on isolated strains.

Main Results:

  • A cattle-level positive rate of 4.64% and a herd-level positive rate of 13.16% were detected.
  • Six BPIV-3C strains were isolated, with phylogenetic analysis indicating close relation to the NX49 strain.
  • The HN, P, and N genes were identified as suitable for BPIV-3 genotyping and evolutionary studies.
  • Evidence of homologous recombination in bovine BPIV-3 was found.
  • Strain Hubei-03 exhibited the highest pathogenicity, suggesting its potential as a vaccine candidate.

Conclusions:

  • This study provides crucial data on BPIV-3 prevalence and genetic diversity in China.
  • The findings support the development of targeted BPIV-3 control measures and vaccine strategies.